Clinical Trial Update: Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension [Phase 2]

View source ↗

Summary

A Phase 2 study of CFZ533, an anti-CD40 monoclonal antibody, in liver transplant recipients was terminated, with results including 12-month follow-up and long-t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplant Rejection

Drugs mentioned

• CFZ533

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Liver Transplant Rejection | Phase 2 | Status: TERMINATED | Results posted: 2024-07-03